Isis has 28 candidates in preclinical and clinical development across a wide variety of indications, with nine scheduled to report data in the next 12 months...The company said it is seeking to improve utilization of prostate cancer vaccine Provenge (sipuleucel-T) by executing a direct-to-consumer (DTC) campaign that began in March, prompting a trend in improved enrollment that began midway through the first quarter

The study was carried out to explore previous clinical findings with cabozantinib in castration-resistant prostate cancer patients with bone metastases showing a 67 percent rate of bone scan response and other clinical signs of effect

The NX03-0040 prostate cancer clinical study of 150 men is testing low (2.5 mg) and high (15 mg) single doses of NX-1207 for the effect to eradicate or shrink low-grade localized prostate cancer tumors

Targeted Medical Pharma Inc., of Los Angeles, said results from an open-label study of oral amino acid-based erythrocyte stimulating system (ESS) for the treatment of chronic anemia showed that hemoglobin increased an average of 11.39 percent from baseline measurement to 45 days...Vertex Pharmaceuticals Inc., of Cambridge, Mass., said VX-787 in a Phase II influenza challenge study resulted in statistically significant improvements in viral and clinical measurements of infection...Also, 93 percent of

Amicus Therapeutics Inc., of Cranbury, N.J., reported positive results from clinical and preclinical studies of the pharmacological chaperone AT2220 (duvoglustat HCl) in combination with ERT for Pompe disease at the Lysosomal Disease Network World Symposium...Based on those results, the company plans to initiate a repeat-dose clinical study in the third quarter of 2013 to evaluate an intravenous formulation of AT2220 co-administered with Myozyme/Lumizyme...BioAlliance Pharma SA, of Paris, said the FDA

The randomized, multicenter, placebo-controlled study also demonstrated statistically significant improvement compared to placebo in the secondary endpoints of median time to opiate use for prostate cancer pain and to initiation of chemotherapy...The data, from the latest pre-specified interim analysis of the study, were presented at the annual American Society of Clinical Oncology Genitourinary Cancers Symposium in Orlando, Fla

The preliminary results from the studies supported the further clinical investigation in patients suffering from advanced prostate cancer, the company said...Dendreon Corp., of Bridgewater, N.J., reported findings from several ongoing or completed studies of Provenge (sipuleucel-T) in advanced prostate cancer ahead of the 2013 American Society of Clinical Oncology Genitourinary Cancers Symposium in Orlando, Fla

As a small biotech with one foot in infectious disease and the other in neurology while having one hand in commercial products and the other in clinical development, "we have a unique strategy, and so far it's working well," Musunuri said...Proceeds will be used for general corporate purposes, including the company's ongoing trials of NX-1207, in late-stage development for benign prostatic hyperplasia and in Phase II testing in prostate cancer.

also participated in the financing, an unusual syndicate formed by investment funds of multiple large pharma companies...The company, which is working on cancer programs, has PSMA ADC, a fully human monoclonal antibody-drug conjugate in Phase II for prostate cancer, and is working on preclinical-stage PI3K inhibitors

The primary endpoint of the study is clinical benefit of AEZS-108...CellAct Pharma GmbH, of Dortmund, Germany, said its topoisomerase inhibitor CAP7...The study, conducted in 20 Asian patients at seven clinical trial sites, compared the outcome of a single intravenous dose of Zybrestat (15, 25, 35 or 45 mg/kg) with placebo

The FDA granted Xtandi (enzalutamide, Astellas Pharma Inc. and Medivation Inc.) approval in September for metastatic castration-resistant prostate cancer patients who have previously received docetaxel. (See BioWorld Today, Sept. 4, 2012.) Dendreon said it is looking for a European marketing partner, rather than just a manufacturing partner

AlphaCore Pharma Inc., of Ann Arbor, Mich., said its Phase I trial met the primary endpoint by demonstrating the safety and tolerability of ACP-501 (recombinant human LCAT...The positive clinical effects of the twice-daily dose of the drug relative to placebo were observed in a variety of standard psoriasis assessment parameters, with the responses accumulating over the 24 weeks...Nymox Pharmaceutical Corp., of Hasbrouck Heights, N.J., said the independent data monitoring committee for its Phase II

Medivation Inc., of San Francisco, and Astellas Pharma Inc., of Tokyo, published Phase III results from the AFFIRM trial of enzalutamide (MDV3100) in metastatic castration-resistant prostate cancer patients previously treated with docetaxel-based chemotherapy in the New England Journal of Medicine

A.P. Pharma Inc., of Redwood City, Calif., said it is raising about $53.6 million through a private placement with certain new and existing institutional investors for 102 million shares priced at 5.25 cents per share...A.P. Pharma is developing APF530, a 5-HT3 antagonist formulated with its Biochronomer drug delivery system, for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting...Shares of A.P. Pharma (OTCBB:APPA) fell 7 cents, or 10.6 percent, to close

Medivation Inc., of San Francisco, and Astellas Pharma Inc., of Tokyo, completed enrollment of 1,680 patients in the Phase III PREVAIL study of enzalutamide for advanced prostate cancer

Antisense Pharma GmbH, of Regensburg, Germany presented complete data from its Phase I/II study of trabedersen, an antisense compound that specifically inhibits expression of transforming growth factor beta 2 (TGF-β2) – a protein which is overexpressed in advanced tumors – in patients with advanced pancreatic cancer, malignant melanoma or colorectal cancer...Bayer AG, of Leverkusen, Germany, reported updated data from its Phase III ALSYMPCA trial for radium-223 dichloride in men with castration

With regulatory filings for its prostate cancer therapy, Alpharadin (radium-223 chloride), expected in mid-2012, Algeta ASA is seeking up to NOK260 million (US$45.4 million) in a private placement to enable it to establish a commercial base in the U.S...The specialty pharma firm also improved its interest terms.

GlobeImmune Inc., of Louisville, Colo., said it started a Phase I trial of GI-6301 , a Targmogen candidate, in patients with metastatic cancers containing brachyury protein, which is overexpressed in tumor types such as breast, colon, lung and prostate cancers...Secondary endpoints include levels of brachyury-specific T cells, reduction in brachyury serum markers and circulating tumor cells and evidence of clinical benefit...Zealand Pharma A/S, of Copenhagen, Denmark, said partner Sanofi SA, of Paris

BioAlliance Pharma SA, of Paris, said results of a Phase I trial showed a satisfactory safety and a signal of efficacy via local administration of its AMEP biotherapy, so the firm is moving into a European Phase I/II trial testing an intramuscular route of delivery of patients with metastatic melanoma...Based on the study's findings, Spectrum plans to expand its clinical development program for Zevalin to include support for a larger study using Z-beam for ASCT...The existing clinical program includes